Jun 11, 2020 / 07:50PM GMT
Salveen Jaswal Richter - Goldman Sachs Group Inc., Research Division - VP
Thank you joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased to have Atara Biotherapeutics here with us. With us, we have Pascal Touchon, CEO; and Jakob Dupont, Head of Research and Development.
And with that, maybe just a big picture question to start here. How are you allocating resources across your portfolio, given the expanding tab-cel program, the MS program, and the emerging Mesothelin, including rest of cell therapy program that you're developing here in parallel?
Pascal Touchon - Atara Biotherapeutics, Inc. - President, CEO & Director
Thank you, Salveen, for your question, and good morning, good afternoon, everyone, and thank you for participating to this Atara Biotherapeutics fireside chat. Yes, we do allocate our resources appropriately according to our strategic priorities and also to deliver on the near-term milestone that we have at Atara, in particular, the initiation of the BLA for tab-cel in its first indication. Also
Atara Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers